search
Back to results

Functional Testing Underlying Coronary Revascularisation (FUTURE)

Primary Purpose

Multivessel Coronary Artery Disease, Vessel Disease, Stable Angina

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
invasive coronary angiography
Functional testing by fractional flow reserve measurement
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Multivessel Coronary Artery Disease focused on measuring fractional flow reserve, multivessel coronary artery disease, angiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age > 18
  • referred to the cardiologist for one of the following medical condition :

    • ST segment elevation myocardial infarction evolving for more than 7 days after revascularization of culprit coronary artery or
    • no ST elevation acute coronary syndrome with or without troponin (T or I) elevation and medically stabilized for at least 12 hours or
    • stable angina (CCS I, II or III) or
    • chest pain diagnosis with suspicion of CAD or with ischemia certificated by non invasive tests.
    • patients with at least 2 vessel disease (≥50% stenosis on angiography) including the left anterior descending coronary artery or with single vessel disease on left main coronary artery
  • Patient willing and able to provide informed, written consent
  • Patient not under legal protection
  • Patient benefiting from the French Health Insurance

Exclusion Criteria:

  • Pregnancy, childbearing, absence of effective contraception
  • Previous coronary bypass surgery
  • Planned associated valvular surgery
  • Life expectancy < 2 years

Sites / Locations

  • HOSPICES

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

FRACTIONAL FLOW RESERVE

ANGIOGRAPHY

Arm Description

Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment. Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8.

Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.

Outcomes

Primary Outcome Measures

composite endpoint that includes the rate of major cardiovascular events defined as a composite of death from any cause, myocardial infarction, any hospitalization leading to additional coronary revascularization, stroke.
The effect of therapeutic strategy will be assessed by the reduction of the incidence of major cardiovascular events in the group "angiography with FFR testing" in comparison to the group "angiography alone". Patients will be prospectively and clinically followed during the duration of the study and all major cardiovascular events will be documented and reported in the electronic case report form.
Bypass graft patency assessed in all CABG patients at one year by coronary multidetector computed tomography .

Secondary Outcome Measures

Major cardiovascular events in all patients, in diabetic patients, by revascularization strategy (angioplasty, coronary artery bypass graft surgery, medical optimal treatment).
The effect of our therapeutic strategy will be assessed upon each category of cardiovascular event individually.
Major cardiovascular events in all patients.
Stent thrombosis.
Bleeding events.
Patient's quality of life
We will use the European Quality of Life-5 Dimensions instrument.
Cost-effectiveness of each therapeutic strategy
NACost-effectiveness of each therapeutic strategy will be assessed by the evaluation of medical costs linked to the pathology (hospitalizations, consultations, and external medical costs (biology, radiology, medications) and compared in the 2 groups during the first 12 months of follow up.
Bypass graft patency assessed in all CABG patients at one year by coronary multidetector computed tomography .

Full Information

First Posted
May 29, 2013
Last Updated
June 27, 2018
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT01881555
Brief Title
Functional Testing Underlying Coronary Revascularisation
Acronym
FUTURE
Official Title
FUnctional Testing Underlying Coronary REvascularisation.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
May 27, 2013 (undefined)
Primary Completion Date
June 10, 2017 (Actual)
Study Completion Date
June 10, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this trial is to compare the clinical outcomes and cost-effectiveness of 2 therapeutic strategies, one based on coronary angiography guidance and the other based on coronary angiography with fractional flow reserve (FFR) in multivessel coronary artery disease patients. The trial is a prospective, multicenter, French, randomized clinical trial including men and women ≥ 18 years presenting with significant multivessel disease defined by coronary angiography as coronary narrowing > 50% diameter stenosis in at least 2 major epicardic vessels. The patients who give their informed consent will be randomly assigned to a therapeutic strategy based upon coronary angiography or angiography with FFR testing. In the FFR group, a significant coronary stenosis will be defined by a FFR ≤ 0.8. Based upon this multivessel evaluation (angiography or FFR), the investigator will choose the best therapeutic strategy to his discretion (medical optimal treatment, coronary stenting, coronary artery bypass graft surgery). The aim of revascularization procedures will be to obtain complete revascularization. In the FFR group, only stenosis with FFR≤0.8 will be treated. The primary end point of the trial is a composite of major cardiovascular events including death from any cause, myocardial infarction, any hospitalization for coronary revascularization performed in addition to initial treatment and stroke at 1 year of follow-up. Secondary end points will include adverse events, individual major cardiovascular events, stent thrombosis, bleeding events, occlusion of coronary artery bypass graft, patient's quality of life and cost-effectiveness and 30-day, 6 month, 2-year and 5-year outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multivessel Coronary Artery Disease, Vessel Disease, Stable Angina, Unstable Angina or Stabilized Non-ST Elevated Myocardial Infarction, Patients With ST-elevated Myocardial Infarction, Revascularization of Culprit Coronary Artery
Keywords
fractional flow reserve, multivessel coronary artery disease, angiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
941 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FRACTIONAL FLOW RESERVE
Arm Type
Other
Arm Description
Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment. Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8.
Arm Title
ANGIOGRAPHY
Arm Type
Other
Arm Description
Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
Intervention Type
Procedure
Intervention Name(s)
invasive coronary angiography
Intervention Type
Procedure
Intervention Name(s)
Functional testing by fractional flow reserve measurement
Intervention Description
Functional testing by fractional flow reserve measurement
Primary Outcome Measure Information:
Title
composite endpoint that includes the rate of major cardiovascular events defined as a composite of death from any cause, myocardial infarction, any hospitalization leading to additional coronary revascularization, stroke.
Description
The effect of therapeutic strategy will be assessed by the reduction of the incidence of major cardiovascular events in the group "angiography with FFR testing" in comparison to the group "angiography alone". Patients will be prospectively and clinically followed during the duration of the study and all major cardiovascular events will be documented and reported in the electronic case report form.
Time Frame
1 year.
Title
Bypass graft patency assessed in all CABG patients at one year by coronary multidetector computed tomography .
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Major cardiovascular events in all patients, in diabetic patients, by revascularization strategy (angioplasty, coronary artery bypass graft surgery, medical optimal treatment).
Time Frame
1 year
Title
The effect of our therapeutic strategy will be assessed upon each category of cardiovascular event individually.
Time Frame
1 year
Title
Major cardiovascular events in all patients.
Time Frame
2 years, 3 years, 4 years and 5 years
Title
Stent thrombosis.
Time Frame
1 year
Title
Bleeding events.
Time Frame
1 year
Title
Patient's quality of life
Description
We will use the European Quality of Life-5 Dimensions instrument.
Time Frame
1 year
Title
Cost-effectiveness of each therapeutic strategy
Description
NACost-effectiveness of each therapeutic strategy will be assessed by the evaluation of medical costs linked to the pathology (hospitalizations, consultations, and external medical costs (biology, radiology, medications) and compared in the 2 groups during the first 12 months of follow up.
Time Frame
1 year
Title
Bypass graft patency assessed in all CABG patients at one year by coronary multidetector computed tomography .
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age > 18 referred to the cardiologist for one of the following medical condition : ST segment elevation myocardial infarction evolving for more than 7 days after revascularization of culprit coronary artery or no ST elevation acute coronary syndrome with or without troponin (T or I) elevation and medically stabilized for at least 12 hours or stable angina (CCS I, II or III) or chest pain diagnosis with suspicion of CAD or with ischemia certificated by non invasive tests. patients with at least 2 vessel disease (≥50% stenosis on angiography) including the left anterior descending coronary artery or with single vessel disease on left main coronary artery Patient willing and able to provide informed, written consent Patient not under legal protection Patient benefiting from the French Health Insurance Exclusion Criteria: Pregnancy, childbearing, absence of effective contraception Previous coronary bypass surgery Planned associated valvular surgery Life expectancy < 2 years
Facility Information:
Facility Name
HOSPICES
City
Lyon
ZIP/Postal Code
69002
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
34736563
Citation
Rioufol G, Derimay F, Roubille F, Perret T, Motreff P, Angoulvant D, Cottin Y, Meunier L, Cetran L, Cayla G, Harbaoui B, Wiedemann JY, Van Belle E, Pouillot C, Noirclerc N, Morelle JF, Soto FX, Caussin C, Bertrand B, Lefevre T, Dupouy P, Lesault PF, Albert F, Barthelemy O, Koning R, Leborgne L, Barnay P, Chapon P, Armero S, Lafont A, Piot C, Amaz C, Vaz B, Benyahya L, Varillon Y, Ovize M, Mewton N, Finet G; FUTURE Trial Investigators. Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease. J Am Coll Cardiol. 2021 Nov 9;78(19):1875-1885. doi: 10.1016/j.jacc.2021.08.061.
Results Reference
derived

Learn more about this trial

Functional Testing Underlying Coronary Revascularisation

We'll reach out to this number within 24 hrs